Community-Acquired MRSA Infections : Treatments

• In vitro evidence suggests TMP/SMX has greater bactericidal activity against community-acquired MRSA than linezolid, rifampin , clindamycin , or minocycline.

• Clindamycin is widely used in children for community-acquired MRSA skin and soft-tissue infections, and is anecdotally reported to be effective.

• Rifampin has excellent in vitro activity against community-acquired MRSA, but it cannot be used by itself because of rapid development of resistance, which can occur during active treatment. Combining rifampin with TMP/SMX, or fusidic acid where available, may be more effective than using either agent alone.

• Parenteral therapy is available for serious community-acquired MRSA infections. Vancomycin remains the first choice for MRSA therapy. 

Reference : 

1. http://www.aafp.org/afp/2009/0501/p802.html